Source: European Medicines Agency (EU) Revision Year: 2026 Publisher: Incyte Biosciences Distribution B.V., Paasheuvelweg 25, 1105 BP Amsterdam, The Netherlands
Povofortay is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults who have responded inadequately to, or who are intolerant or contraindicated to an anti-TNF therapy.
Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of hidradenitis suppurativa.
The dose is 45 mg or 75 mg once daily based on individual patient characteristics:
Consideration should be given to discontμία φορά την ημέραinuing treatment in patients who have shown no evidence of therapeutic benefit after 12 weeks of treatment. Patients with an initial partial response at week 12 may subsequently improve with continued treatment.
If retreatment with povorcitinib is indicated, the above guidance on dose and treatment duration should be followed.
Treatment with povorcitinib should not be initiated in patients with a platelet count <50 × 109/L, an absolute neutrophil count (ANC) <1 × 103/mm³, or who have a haemoglobin value <8 g/dL (see section 4.4).
Guidance for laboratory monitoring and dose initiation or interruption is provided in Table 1.
Table 1. Laboratory tests and monitoring guidance:
| Laboratory test | Action | Monitoring guidance | |
| Complete blood count including platelet count, haemoglobin (Hb), and absolute neutrophil count (ANC) | Treatment should be interrupted if platelet counts are <50 × 109/L. Treatment may be restarted once platelet count returns above this value. | Before treatment initiation and thereafter according to individual patient management. | |
| Treatment should be interrupted if Hb is <8 g/dL. Treatment may be restarted once Hb returns above this value. | |||
| Treatment should be interrupted if ANC <1 × 103/mm³. Treatment may be restarted once neutrophil count returns above this value. | μία φορά την ημέρα | Lipids | Patients should be monitored according to clinical guidelines for hyperlipidaemia. |
If a patient develops a serious infection, treatment should be interrupted until the infection is controlled (see section 4.4).
Interruption of dosing may be needed for management of laboratory abnormalities as described in Table 1.
If a dose is missed, patients should be advised to take the dose as soon as possible unless it is less than 12 hours before the next dose, in which case the patient should not take the missed dose. Thereafter, dosing should be resumed at the regular scheduled time.
For patients receiving chronic treatment with strong systemic CYP3A4 inhibitors, the recommended dose is 45 mg once daily (see section 4.5). Co-administration of povorcitinib with chronic use of strong systemic CYP3A4 inducers is not recommended (see section 4.5).
For patients 65 years of age and older, the recommended dose is 45 mg once daily (see section 4.4).
No dose adjustment is required in patients with renal impairment, including patients with end stage renal disease (ESRD) (see section 5.2).
No dose adjustment is required in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment (see section 5.2). For patients with severe (Child-Pugh C) hepatic impairment, the maximum recommended dose is 45 mg once daily (see section 5.2).
There is no relevant use of povorcitinib in children under 12 years of age for the treatment of hidradenitis suppurativa.
The safety and efficacy of povorcitinib in children and adolescents between 12 and less than 18 years of age have not yet been established. No data are available.
For oral use.
Tablets can be taken with or without food. Tablets should be swallowed whole and should not be split, crushed or chewed.
Povorcitinib was administered in clinical studies up to single oral doses of 450 mg once daily (6 times the recommended human dose of 75 mg once daily) and multiple oral doses up to 120 mg once daily for 10 days. Adverse reactions were comparable to those seen at lower doses and no specific toxicities were identified. Pharmacokinetics data in healthy adult participants indicate that more than 90% of the administrated dose up to 450 mg is expected to be eliminated after 5 days.
In the event of overdose, it is recommended that the patient be monitored for any signs and symptoms of adverse reactions (see section 4.8) and appropriate symptomatic treatment be instituted immediately.
2 years.
This medicinal product does not require any special storage conditions.
PVC-PCTFE/Aluminium blister containing 14 film-coated tablets. Each carton contains 28 or 98 tablets.
Not all pack sizes may be marketed.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.